High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23

@article{Dahlerup2016HighdoseFI,
  title={High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23},
  author={J. Dahlerup and B. Jacobsen and J. C. van der Woude and Lars-{\AA}ke Bark and L. Thomsen and S. Lindgren},
  journal={Scandinavian Journal of Gastroenterology},
  year={2016},
  volume={51},
  pages={1332 - 1338}
}
  • J. Dahlerup, B. Jacobsen, +3 authors S. Lindgren
  • Published 2016
  • Medicine
  • Scandinavian Journal of Gastroenterology
  • Abstract Objective: Iron isomaltoside (Monofer®) is a high-dose intravenous iron preparation with good tolerability and efficacy in inflammatory bowel disease (IBD) patients with iron deficiency anaemia (IDA). This trial evaluates the safety and efficacy, including effect on intact fibroblast growth factor 23 (iFGF23) of a high single dose and cumulative doses of iron isomaltoside in IBD patients with IDA. Materials and methods: The trial was a prospective, open-label, multi-centre trial… CONTINUE READING
    25 Citations
    Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial
    • 15
    A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy
    • L. Huang, D. Lee, +4 authors L. McMahon
    • Medicine
    • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
    • 2018
    • 19
    • PDF

    References

    SHOWING 1-10 OF 30 REFERENCES
    A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease
    • 27
    A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia
    • P. Kalra, S. Bhandari, +5 authors D. Coyne
    • Medicine
    • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
    • 2016
    • 49
    • PDF
    A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients
    • S. Bhandari, P. Kalra, +6 authors D. Coyne
    • Medicine
    • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
    • 2015
    • 43
    • PDF
    When is high-dose intravenous iron repletion needed? Assessing new treatment options
    • 58
    • PDF
    A Randomized, Open-Label, Non-Inferiority Study of Intravenous Iron Isomaltoside 1,000 (Monofer) Compared With Oral Iron for Treatment of Anemia in IBD (PROCEED)
    • 103
    • PDF
    Intravenous Iron Therapy in Patients with Iron Deficiency Anemia: Dosing Considerations
    • 44
    • PDF
    Severe hypophosphataemia after intravenous iron administration.
    • 55